Novaliq GmbH said yesterday that it named Christian Roesky as its new CEO, replacing co-founder Bernhard Günther, who will take on a new role as chief innovation officer.
The Heidelberg, Germany-based company focuses on renovating poorly soluble drugs into effective ocular therapeutics. Its CE-marked product, NovaTears, was developed from its proprietary EyeSol technology. With its reshuffled executive team, Novaliq said it hopes to continue developing therapeutics for ophthalmic indications such as dry eye, glaucoma and retina diseases.
“We are very pleased to have Christian join Novaliq’s senior executive team as CEO,” chairman Friedrich von Bohlen said in prepared remarks. “His experience and proven leadership will be highly beneficial as we move our many drug candidates through product development, clinical trials, approvals and commercialization. I want to recognize and thank Bernhard for his numerous contributions to Novaliq. As the company’s co-founder, Bernhard has led Novaliq to develop a unique ocular therapeutics delivery technology, to raise capital, and to hire a world-class team that has resulted in the development of the current line of innovative products and the successful market launch of NovaTears, the first innovative EyeSol product. Under Christian’s leadership and Bernhard’s continued support and guidance, I am confident that Novaliq will continue to drive exceptional growth and reach its business goals.”
“It’s a very exciting time to join Novaliq,” Roesky added. “In the past year, Novaliq has made tremendous progress to address unmet medical needs, which is strongly demonstrated by the successful launch of EvoTears in Europe. The success of this launch emphasizes the benefits and efficacy of EyeSol technology positioning us well for the future. I look forward to working with the talented Novaliq team to deliver products that make a real difference to patients suffering from dry eye, glaucoma and retinal diseases.”
“As company founder and entrepreneur, I am keenly aware of the important clinical benefits our EyeSol delivery technology brings to our products,” Günther said. “I look forward to working with Christian and the Novaliq team in my new role to continue to advance the development of our EyeSol based dry eye, glaucoma and retina products.”
